One-Dose immunotherapy before surgery shows promise for advanced melanoma
NCT ID NCT07349303
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether one dose of the immunotherapy drug pembrolizumab, given before standard surgery, can shrink or eliminate tumors in people with stage IIb/c melanoma. About 30 adults with thick melanomas that haven't spread to lymph nodes will receive either pembrolizumab or a placebo, then have surgery four weeks later. The main goal is to see how many patients have a significant reduction in tumor cells after just one treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, 41345, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer light up hidden cancers?
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Which High-Tech camera is better at spotting skin cancer?
- Could a Two-Drug combo reawaken the immune system against resistant cancers?
- Blood test may let cancer patients take safe breaks from immunotherapy
- Precision radiation meets new drugs in fight against brain metastases from melanoma